Case Report

Mitochondrial Cardiomyopathy Presenting as Dilated Phase of Hypertrophic Cardiomyopathy Diagnosed with Histological and Genetic Analyses

Toshiki Kuno,1 Syohei Imaeda,1 Yohei Asakawa,2 Hiroshi Nakamura,3 Genzou Takemura,4 Daisuke Asahara,2 Akira Kanamori,5 Tomoyuki Kabutoya,6 and Yohei Numasawa1

1Department of Cardiology, Japanese Red Cross Ashikaga Hospital, Ashikaga, Japan
2Department of Neurology, Japanese Red Cross Ashikaga Hospital, Ashikaga, Japan
3Department of General Internal Medicine, Hiroshima-Nishi Medical Center, Ohtake, Japan
4Department of Internal Medicine, Asahi School of Dentistry University, Mizuho, Japan
5Department of Gastroenterology, Japanese Red Cross Ashikaga Hospital, Ashikaga, Japan
6Department of Cardiology, Jichi Medical University, Shimotsuke, Japan

Correspondence should be addressed to Toshiki Kuno; kuno-toshiki@hotmail.co.jp

Received 3 March 2017; Accepted 4 May 2017; Published 23 May 2017

Copyright © 2017 Toshiki Kuno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We report a case with 46-year-old man diagnosed with mitochondrial cardiomyopathy in the dilated phase of hypertrophic cardiomyopathy. Since cardiac magnetic resonance imaging, beta-methyl-p-123I-iodophenyl-pentadecanoic myocardial scintigraphy, and positron emission tomography/computed tomography revealed no remarkable findings, we performed electron microscopic examination, which aided in diagnosing mitochondrial cardiomyopathy. Muscle biopsy was also compatible with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes and DNA analysis also concluded it. Since muscle biopsy is less invasive for patients compared to endomyocardial biopsy, cardiologists need to consider it. The diagnosis of mitochondrial cardiomyopathy is helpful because it is a genetic condition and also for consideration of device therapy, as well as management for acute crisis.

1. Introduction

Mitochondrial disease is a heterogeneous group of multisystemic diseases due to mutations in nuclear or mitochondrial DNA. Although multimodality aids the diagnosis, the diagnosis of mitochondrial cardiomyopathy is challenging because histological analysis is sometimes needed [1–3]. We report a case with 46-year-old man diagnosed with mitochondrial cardiomyopathy in the dilated phase of hypertrophic cardiomyopathy diagnosed with muscle and endomyocardial biopsy and genetic analyses.

2. Case Report

A 46-year-old man visited an outpatient clinic complaining of appetite loss since a month ago. He was lean with short stature, weighing 31 kg, and 157 cm tall. He had been diagnosed with hypertrophic cardiomyopathy at the age of 40 years and had sensory hearing loss and diabetes mellitus. An echocardiography one year ago showed diffuse left ventricular hypertrophy (interventricular-septal wall thickness: 12 mm, lateral wall thickness: 14 mm) with an ejection fraction of 52%. His mother had died at the age of 50 due to dilated cardiomyopathy and had a history of diabetes mellitus. His brother also suffered hearing loss. The patient was a nonsmoker with no history of hypertension. His electrocardiogram revealed normal sinus rhythm and complete left bundle branch block (QRS duration: 128 ms) (Figure 1(a)). B-type natriuretic peptide was 176 pg/mL and troponin-T level was 0.18 ng/mL. Echocardiography revealed severely compromised left ventricular systolic function, except the lateral wall, with an ejection fraction of 20% (Figures 1(b) and 1(c), Online video supplement 1, Supplementary Material available online at https://doi.org/10.1155/2017/9473917).
Serum lactate and pyruvate levels and cerebrospinal fluid lactate and pyruvate levels were elevated (24.4, 1.2, and 41.8, 1.4 mg/dL, resp.). Cardiac magnetic resonance imaging (MRI) showed no late gadolinium enhancement (LGE); positron emission tomography/computed tomography (PET-CT) showed no remarkable findings (Figures 1(d) and 1(e)). Beta-methyl-p-\(^{123}\)I-iodophenyl-pentadecanoic (\(^{123}\)I-BMIPP) myocardial scintigraphy revealed diffuse reduced uptake, except on the lateral wall (Figure 1(f)). Coronary angiography showed intact arteries. Endomyocardial biopsy revealed vacuolar changes in the myocardial cells (especially around nucleus) and perimysial fibrosis without inflammatory cells (Figure 2(a)). Electron microscopic examination showed increased numbers of mitochondria with various types of deformations, differences in size, and rare fraction of myofibril (Figure 2(b)). Since the patient was quite lean, we performed a muscle biopsy, which revealed ragged red fibers without cytochrome c oxidase activity, which is compatible with mitochondrial myopathy (Figures 2(c)–2(e)). Finally, mitochondrial DNA analysis of his blood sample showed m.3243A>G mutation and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome. However, he denied any symptoms such as weakness and his MRI of the head did not show any remarkable findings.

The diagnosis was concluded as mitochondrial cardiomyopathy and MELAS. After treatment with intravenous dobutamine for reduced output, he was given angiotensin-converting enzyme inhibitor, beta-blocker, spironolactone, coenzyme Q10, and carnitine. Since he complained of nausea after dobutamine therapy, we performed a gastroscopy and stomach biopsy. Electron microscopic examination showed no mitochondrial deformation (Figure 2(f)). At 7 months’ follow-up after medical therapy, echocardiography revealed no change in systolic dysfunction and he had mild dyspnea on exertion (New York Heart Association, Class II). Troponin-T level remained elevated (0.18 ng/mL). He was then referred to another institute for the possibility of cardiac resynchronization and intracardiac defibrillation device therapy.

3. Discussion

We report a case, diagnosed with mitochondrial cardiomyopathy in the dilated phase of hypertrophic cardiomyopathy. Although 30% of cases of mitochondrial myopathy showed LGE, the MRI in our case revealed no significant findings in contrast to a previous study [2]. PET-CT in our case showed unremarkable findings as well. There is no published report of mitochondrial cardiomyopathy and PET-CT. Moreover, \(^{123}\)I-BMIPP myocardial scintigraphy revealed diffuse reduced uptake except in the lateral wall and fatty acid metabolism disturbances, but it was indefinite because another study insisted \(^{123}\)I-BMIPP hyperaccumulation is related to mitochondrial cardiomyopathy [3]. If we performed myocardial
perfusion imaging, we would observe a metabolic-perfusion mismatch because of the intact coronary arteries. Since multimodal investigations revealed no conclusive findings, we performed electron microscopic examination, which aided in diagnosing mitochondrial cardiomyopathy [4]. Muscle biopsy was also compatible with MELAS and DNA analysis concluded MELAS. Since muscle biopsy is less invasive for patients compared to endomyocardial biopsy [5], cardiologists need to consider it. The diagnosis of mitochondrial cardiomyopathy as seen in our case is helpful because it is a genetic condition and also for consideration of device therapy, as well as management for acute crisis [6]. In our case, we could expect the response to CRT-D to decrease the risk of cardiac sudden death and heart failure symptoms, although cardiac MRI scan showed no LGE, which might suggest favorable outcomes [6–8].

4. Conclusion

We report a case of mitochondrial cardiomyopathy presenting as dilated phase of hypertrophic cardiomyopathy diagnosed with muscle and endomyocardial biopsy and genetic analyses. Since muscle biopsy is less invasive for patients compared to endomyocardial biopsy, cardiologists need to consider it regardless of muscle weakness.

Conflicts of Interest

The authors report no conflicts of interest.

References

[1] D. E. Meyers, H. I. Basha, and M. K. Koenig, “Mitochondrial cardiomyopathy: pathophysiology, diagnosis, and management,” *Texas Heart Institute Journal from the Texas Heart Institute of St Luke’s Episcopal Hospital, Texas Children’s Hospital*, vol. 40, no. 1, pp. 385–394, 2013.

[2] M. Nakanishi, M. Harada, E. Tadamura et al., “Mitochondrial cardiomyopathy evaluated with cardiac magnetic resonance,” *Circulation*, vol. 116, no. 2, pp. e25–e26, 2007.

[3] S. Matsuo, K. Nakajima, S. Knuya, Y. Sato, N. Matsumoto, and M. Horie, “Cardiac scintigraphic findings of mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes: A case report,” *Experimental and Clinical Cardiology*, vol. 13, no. 2, pp. 93–95, 2008.

[4] G. Takemura, K. Onoue, T. Kashimura et al., “Electron microscopic findings are an important aid for diagnosing mitochondrial cardiomyopathy with mitochondrial dna mutation 3243A>G,” *Circulation Heart failure*, vol. 9, no. 7, 2016.

[5] M. Holzmann, A. Nicko, U. Kühl et al., “Complication rate of right ventricular endomyocardial biopsy via the femoral approach: A retrospective and prospective study analyzing 3048
diagnostic procedures over an 11-year period," *Circulation*, vol. 118, no. 17, pp. 1722–1728, 2008.

[6] Y.-H. R. Hsu, H. Yogasundaram, N. Parajuli, L. Valtuille, C. Sergi, and G. Y. Oudit, “MELAS syndrome and cardiomyopathy: linking mitochondrial function to heart failure pathogenesis,” *Heart Failure Reviews*, vol. 21, no. 1, pp. 103–116, 2016.

[7] A. S. L. Tang, G. A. Wells, M. Talajic et al., “Cardiac-resynchronization therapy for mild-to-moderate heart failure,” *New England Journal of Medicine*, vol. 363, no. 25, pp. 2385–2395, 2010.

[8] Z. Weng, J. Yao, R. H. Chan et al., “Prognostic Value of LGE-CMR in HCM,” *JACC: Cardiovascular Imaging*, vol. 9, no. 12, pp. 1392–1402, 2016.